Recent findings have shown that the biologics market in the Asia Pacific region will reach over $625 million (USD) by 2026 with a compound annual growth rate (CAGR) of 13%.
To keep up with this growing demand, our Biologics Testing Solutions team is excited to announce the opening of two new offices in China and Singapore, joining our existing locations in Japan, Taiwan, India, and South Korea. These offices support sales and project management for biologics research in conjunction with our other locations around the world.
"Our local presence will help us better support the needs of our customers, develop closer relationships with our clients in the region, and respond to their demands more quickly," said Nadiya Kravchuk, Associate Director of Biologics Sales for Asia Pacific.
"We look forward to working with our clients in Asia and expanding our footprint in a rapidly growing part of the world."
Charles River's expansion in Asia helps serve regional and global organizations with their manufacturing and product release needs. We can support your research throughout the drug development pipeline, from the establishment and characterization of cell banks through preclinical and clinical studies to marketed release.